Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | XBP1 | P17861 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8656719 | 0.84 | LMNA (0.48) | ALDH1A1NPC1RAB9APDE2ALMNA | |
| SCHEMBL11834614 | 0.80 | ALDH1A1 (0.46) | ALDH1A1NPC1RAB9APDE2ALMNA | |
| SCHEMBL26927508 | 0.78 | ALDH1A1 (0.38) | ALDH1A1NPC1RAB9APDE2ALMNA | |
| SCHEMBL6401649 | 0.77 | ALDH1A1 (0.53) | ALDH1A1NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL8198679 | 0.76 | PDE2A (0.52) | ALDH1A1NPC1RAB9APDE2ALMNA | |
| SCHEMBL29693606 | 0.76 | LMNA (0.50) | ALDH1A1NPC1RAB9APDE2ALMNA | |
| SCHEMBL504020 | 0.76 | LMNA (0.50) | ALDH1A1NPC1RAB9APDE2ALMNA | |
| SCHEMBL4254844 | 0.75 | — | — | |
| SCHEMBL13068145 | 0.75 | ALDH1A1 (0.41) | ALDH1A1NPC1RAB9APDE2ALMNA | |
| SCHEMBL29214462 | 0.74 | ALDH1A1 (0.39) | ALDH1A1NPC1RAB9APDE2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788326-B1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RES & DEV (FR) | 2019-04-24 | — | — | EP | disclosed |
| CN-104185627-B | Pyridone Derivatives | 第三共株式会社 | 2018-01-12 | — | — | CN | disclosed |
| US-9732044-B2 | N-(pyrid-4-yl)amides and N-(pyrimidin-4-yl)amides and their pharmaceutical and cosmetic use | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-08-15 | — | — | US | disclosed |
| US-20170066725-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-03-09 | — | — | US | disclosed |
| US-9452120-B2 | N-(pyrid-4-yl)amides and N-(pyrimidin-4-yl)amides and their pharmaceutical and cosmetic use | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-09-27 | — | — | US | disclosed |
| EP-2788326-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | Galderma Research & Development (FR) | 2014-10-15 | — | — | EP | disclosed |
| US-20140234245-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-08-21 | — | — | US | disclosed |
| WO-2013064681-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234245-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | NR5A1, AR, CYP19A1 | ALDH1A1 1847/4885NPC1 1535/4885RAB9A 4370/4885 |
| US-20170066725-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | AR, NR5A1, PPARA | ALDH1A1 2442/4885NPC1 1698/4885RAB9A 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.